2-aminoaryloxazole compounds as tyrosine kinase inhibitors
US8110591B2 · kind B2 · utility
0Cited by
33References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 11, 2010 |
| Grant date | Feb 7, 2012 |
| Priority date | — |
| Expiry date | Apr 23, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel compounds selected from 2-aminoaryloxazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.